{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:45:44Z","timestamp":1790959544767,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>PD-1 inhibitors have been routinely used in the treatment of advanced non-small cell lung cancer (NSCLC), and have demonstrated to significantly improve survivorship when combining with other conventional therapies, such as chemotherapy and anti-angiogenesis therapy. PD-L1 is the most commonly used biomarker to select benefiting groups, while not all patients with high PD-L1 expression benefit from immunotherapy. Therefore, identifying other prognostic and predictive biomarkers, including peripheral blood indexes, is essential.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively collected medical records and hematological data of 151 patients with advanced NSCLC treated with PD-1 inhibitor-based combination therapy in our hospital. The peripheral blood indexes of interest were NLR, PLR, PAR, Hb, LDH, CEA, and NSE. The association between peripheral blood indexes and treatment responses or survival outcomes was examined by multivariable logistic regression and Cox regression, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The decreased CEA at week 6 (OR = 4.209, 95%CI: 1.287-13.758) or 12 (OR = 7.267, 95%CI: 1.508-35.006) post-treatment was related to a higher disease control rate. The decrease or NLR at week 6 (OR = 3.081, 95%CI: 1.464-6.483) or 12 (OR = 3.304, 95%CI: 1.560-7.001) post-treatment, or CEA at week 12 post-treatment (OR = 2.469, 95%CI: 1.134-5.375), was associated with a higher objective response rate. Patients whose NLR (HR = 0.610, 95%CI: 0.411-0.907) or CEA (HR = 0.477, 95%CI: 0.320-0.710) decreased at week 6 post-treatment tended to have longer progression-free survival, and similar results were found in those with decreased NLR (HR = 0.587, 95%CI: 0.388-0.886) or CEA (HR = 0.406, 95%CI: 0.270-0.609) at week 12 post-treatment. Patients whose CEA (HR = 0.543, 95%CI: 0.339-0.871) or NSE (HR = 0.619, 95%CI: 0.386-0.994) decreased after 6 weeks post-treatment appeared to have longer overall survival, and the same was found for those whoseCEA (HR = 0.620, 95%CI: 0.390-0.986) or NSE (HR = 0.578, 95%CI: 0.353-0.947) was decreased at 12 weeks after\u00a0treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Post-treatment NLR, CEA and NSE changes are suggestive indicators for the prognosis of NSCLC patients after immunotherapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.672271","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T09:28:04Z","timestamp":1620984484000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Association of Dynamic Changes in\u00a0Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Yuzhong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaodi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banzhou","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab Versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Keynote-042): A Randomised, Open-Label, Controlled, Phase 3 Trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab Plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and Pemetrexed With or Without Pembrolizumab for Advanced, Non-Squamous Non-Small-Cell Lung Cancer: A Randomised, Phase 2 Cohort of the Open-Label Keynote-021 Study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2020.1816173","article-title":"Promising Predictors of Checkpoint Inhibitor Response in NSCLC","volume":"20","author":"Alex","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.21037\/tlcr-19-583","article-title":"Neutrophil-to-Lymphocyte Ratio in Combination With PD-L1 or Lactate Dehydrogenase as Biomarkers for High Pd-L1 Non-Small Cell Lung Cancer Treated With First-Line Pembrolizumab","volume":"9","author":"Banna","year":"2020","journal-title":"Trans Lung Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1758835920970049","article-title":"Pretreatment Hemoglobin Level as a Predictor to Evaluate the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer","volume":"12","author":"Zhang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1758835920952994","article-title":"CEA and CYFRA 21-1 as Prognostic Biomarker and as a Tool for Treatment Monitoring in Advanced Nsclc Treated With Immune Checkpoint Inhibitors","volume":"12","author":"Dall\u2019Olio","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13505","article-title":"Sarcopenia and High NLR are Associated With the Development of Hyperprogressive Disease After Second-Line Pembrolizumab in Patients With Nonsmall-Cell Lung Cancer","volume":"202","author":"Petrova","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00913","article-title":"Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy","volume":"10","author":"Jiang","year":"2020","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02637-1","article-title":"Variation in Neutrophil to Lymphocyte Ratio (NLR) as Predictor of Outcomes inMetastatic Renal Cell Carcinoma (mRCC) and Non-Small Cell Lung Cancer (Mnsclc) Patients Treated With Nivolumab","volume":"69","author":"Simonaggio","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.06.10","article-title":"Prognostic Role of Pretreatment Neutrophil-to-Lymphocyte Ratio in Non-Small Cell Lung Cancer Patients Treated With Systemic Therapy: A Meta-Analysis","volume":"8","author":"Wang","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2024","article-title":"Pretreatment Lactate Dehydrogenase may Predict Outcome of Advanced Non Small-Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Meta-Analysis","volume":"8","author":"Zhang","year":"2019","journal-title":"Cancer Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2092-x","article-title":"Post-Treatment Neutrophil-to-Lymphocyte Ratio at Week 6 is Prognostic in Patients With Advanced Non-Small Cell Lung Cancers Treated With anti-PD-1 Antibody","volume":"67","author":"Suh","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12967-019-1828-0","article-title":"The Role of CEA, CYFRA21-1 and NSE in Monitoring Tumor Response to Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients","volume":"17","author":"Bello","year":"2019","journal-title":"J Trans Med"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-95228-4_46","article-title":"The Response Evaluation Criteria in Solid Tumors (Recist)","volume-title":"Predictive Biomarkers in Oncology: Applications in Precision Medicine","author":"Lathrop","year":"2019"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunityss, Inflammation, and Cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14381","article-title":"Neutrophils Dominate the Immune Cell Composition in Non-Small Cell Lung Cancer","volume":"8","author":"Kargl","year":"2017","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2583","article-title":"Tumor-Associated Neutrophils: New Targets for Cancer Therapy","volume":"71","author":"Gregory","year":"2011","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of Tumor-Associated Neutrophil Phenotype by TGF-\u03b2: \u201cN1\u201d Versus \u201cN2\u201d Tan","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001845","article-title":"Prospective Development and Validation of a Liquid Immune Profile-Based Signature (LIPS) to Predict Response of Patients With Recurrent\/Metastatic Cancer to Immune Checkpoint Inhibitors","volume":"9","author":"Zhou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment Neutrophil-to-Lymphocyte Ratio and Mutational Burden as Biomarkers of Tumor Response to Immune Checkpoint Inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40425-018-0315-0","article-title":"Change in Neutrophil-to-Lymphocyte Ratio (NLR) in Response to Immune Checkpoint Blockade for Metastatic Renal Cell Carcinoma","volume":"6","author":"Lalani","year":"2018","journal-title":"J Immunotherapy Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01229-w","article-title":"Neutrophil-to-Lymphocyte Ratio (Nlr), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes With Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study","volume":"37","author":"Russo","year":"2020","journal-title":"Adv Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.04.008","article-title":"Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non\u2013Small-Cell Lung Cancer","volume":"19","author":"Zer","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.lungcan.2020.04.034","article-title":"Serum Markers Associated With Treatment Response and Survival in Non-Small Cell Lung Cancer Patients Treated With anti-PD-1 Therapy","volume":"145","author":"Takada","year":"2020","journal-title":"Lung Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.5761\/atcs.oa.20-00090","article-title":"Preoperative Platelet to Albumin Ratio Predicts Outcome of Patients With Non-Small-Cell Lung Cancer","volume":"27","author":"Guo","year":"2020","journal-title":"ATCS"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2015.1043026","article-title":"Prognostic Role of Lactate Dehydrogenase in Solid Tumors: A Systematic Review and Meta-Analysis of 76 Studies","volume":"54","author":"Petrelli","year":"2015","journal-title":"Acta Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jtho.2017.10.030","article-title":"Peripheral Blood Biomarkers Associated With Clinical Outcome in Non\u2013Small Cell Lung Cancer Patients Treated With Nivolumab","volume":"13","author":"Tanizaki","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1001\/jamaoncol.2019.1747","article-title":"Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non\u2013Small Cell Lung Cancer","volume":"5","author":"Kazandjian","year":"2019","journal-title":"JAMA Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lungcan.2019.05.033","article-title":"Early Serum Tumor Marker Dynamics Predict Progression-Free and Overall Survival in Single Pd-1\/Pd-L1 Inhibitor Treated Advanced Nsclc\u2014a Retrospective Cohort Study","volume":"134","author":"Lang","year":"2019","journal-title":"Lung Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.7150\/jca.49213","article-title":"Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer","volume":"11","author":"Huang","year":"2020","journal-title":"J Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102085","article-title":"Clinical Features Affecting Survival in Metastatic Nsclc Treated With Immunotherapy: A Critical Review of Published Data","volume":"89","author":"Passaro","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lungcan.2018.02.017","article-title":"Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer: A Multicenter Retrospective Cohort Study","volume":"119","author":"Fujimoto","year":"2018","journal-title":"Lung Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.12.027","article-title":"Immunotherapy in Advanced Non-Small Cell Lung Cancer Patients With Poor Performance Status: The Role of Clinical-Pathological Variables and Inflammatory Biomarkers","volume":"152","author":"Lobefaro","year":"2021","journal-title":"Lung Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nrcliNonc.2016.211","article-title":"Radiotherapy and Immunotherapy: A Beneficial Liaison","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non\u2013Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.10.002","article-title":"Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage Iii NSCLC\u2014Update From Pacific","volume":"15","author":"Gray","year":"2020","journal-title":"J Thoracic Oncol"}],"updated-by":[{"DOI":"10.3389\/fimmu.2021.713268","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.672271\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T09:24:59Z","timestamp":1623057899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.672271\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2021.672271"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.672271","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fimmu.2021.713268","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]},"article-number":"672271"}}